- Dialco Medical, a subsidiary of Spectral Medical, has announced that Health Canada has granted the company a license for its DIMI system
- The Health Canada license allows for the immediate use of the DIMI systems in hospitals, clinics, and homes
- Spectral Medical Inc develops and markets a treatment for septic shock
- Spectral Medical (EDT) is up 5.77 per cent and is currently trading at C$0.55 per share
Dialco Medical, a subsidiary of Spectral Medical, has announced that Health Canada has granted the company a license for its DIMI system.
The DIMI renal replacement system is based on a fully integrated cassette technology.
As per the Health Canada license, DIMI is a prescription-only medical device, indicated for hemodialysis, hemodiafiltration, and ultrafiltration for patients weighing 20 kgs or more.
“With DIMI licensed in Canada, Dialco can continue to move down its commercialization pathways,” said Dr. Gualtiero Guadagni, President of Dialco Medical.
“DIMI’s versatility addresses many of the barriers to adoption for home hemodialysis, and positions DIMI as the ideal device for multiple segments of chronic dialysis patients across Canada.”
The Health Canada license allows for the immediate use of the DIMI systems in hospitals, clinics, and homes.
Compared to similar devices made by competitors, DIMI is versatile, portable, and requires no major home renovations for use in the home.
It is easy to use and does not require patients or caregivers to undergo extensive training or maintenance to use the device.
Spectral Medical Inc develops and markets a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic.
Spectral Medical (EDT) is up 5.77 per cent and is currently trading at C$0.55 per share as of 11:19 am ET.
